To the Editor.
—We have read with interest the article by Arsura et al1 concerning 12 cases that were treated with high-dose intravenous immunoglobulin therapy for exacerbations of generalized myasthenia gravis. As all of their patients had elevated acetylcholine-receptor antibody (AChR) titers, the authors theorized that a possible mechanism of this therapy is the interference of the interaction of the acetylcholine receptor with AChR antibody. Nevertheless, we have recently described2 a 14-year-old patient with myasthenia gravis without AChR antibody who was successfully treated with high-dose intravenous immunoglobulin therapy. A diagnosis of congenital myasthenic syndrome had been excluded. Our patient was classified as grade III according to the criteria of Osserman. She experienced a severe exacerbation of the disease. High-dose prednisone and anticholinesterase therapies failed to improve her condition within 45 days. Intravenous 7S immunoglobulin was administered with a loading dose of 400 mg/kg daily over five consecutive days.
Bonaventura I, PONSETI J, Arnau E, Matias-Guiu J, Puiggros AC. High-Dose Intravenous Immunoglobulin in the Management of Myasthenia Gravis. Arch Intern Med. 1987;147(2):207–211. doi:10.1001/archinte.1987.00370020027019
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: